Zacks Research Upgrades Eton Pharmaceuticals to Strong-Buy

The pharmaceutical company's stock receives a positive rating boost from analysts.

Mar. 21, 2026 at 11:27am

Got story updates? Submit your updates here. ›

Zacks Research has upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) from a "hold" rating to a "strong-buy" rating in a new report. The upgrade comes as the company continues to develop and commercialize generic and proprietary pharmaceutical products for patients with rare and underserved diseases.

Why it matters

The Zacks upgrade is a positive sign for Eton Pharmaceuticals, which has been working to expand its portfolio of specialty pharmaceutical offerings. The strong-buy rating could help boost investor confidence and potentially drive up the company's stock price as it looks to capitalize on opportunities in niche treatment areas.

The details

In their report, Zacks Research cited Eton's progress in developing and launching new products as a key factor behind the upgrade. The company has a pipeline of thyroid hormone replacements and other specialty drugs targeting areas with limited competition. Eton has also received positive feedback from the FDA on several of its product candidates.

  • Zacks Research issued the upgrade on Thursday, March 21, 2026.

The players

Eton Pharmaceuticals

A specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary products for patients with rare and underserved diseases.

Zacks Research

An investment research firm that provides stock analysis and recommendations to investors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The Zacks upgrade underscores Eton Pharmaceuticals' potential as it works to expand its portfolio of specialty pharmaceutical products targeting underserved patient populations. This positive development could help drive increased investor interest and support the company's growth strategy in the months ahead.